Table 4.
Corrected percentage contribution of Tg-positive cells in E9.5 3n↔2n and 2n↔2n chimeras.
| Epiblast derivatives | Primitive endoderm derivatives | Trophectoderm derivatives | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chimera | Fetus | Amnion | YS mes | Allantois | YS end | P end | PT | PTGC | RMGC | Chorion |
| 3n↔2n chimerasa | ||||||||||
| TrC-26 | Absent | Absent | 9.5 | 64.5 | 3.0 | 0.0 | 0.0 | 0.0 | ||
| TrC-11 | 0.0 | 0.0 | 0.0 | 18.8 | 0.8 | 0.0 | 0.0 | 0.0 | ||
| TrC-8 | 0.6 | ND | 0.0 | 11.2 | 13.4 | 0.0 | 0.0 | 0.0 | ||
| TrB-6 | 1.8 | 0.0 | 0.0 | 12.0 | 12.7 | 14.3 | 0.0 | 0.0 | ||
| TrC-16 | 1.8 | 3.4 | 2.5 | 5.8 | 6.7 | 0.3 | 0.0 | 0.0 | ||
| TrC-37 | 10.7 | ND | 6.9 | 0.9 | 1.9 | 17.0 | ND | 3.0 | ||
| TrC-22 | 11.6 | 5.5 | 13.6 | 54.8 | 27.3 | 73.2 | 0.0 | 20.9 | ||
| TrB-3b | 28.2 | 24.1 | 37.0 | 38.0b | 14.9 | 20.2 | ND | ND | 71.2 | 88.0b |
| Mean±s.e.m. | 7.8±3.9 | 6.6±4.5 | 8.7±4.4 | 22.9±8.3 | 10.8±3.3 | 15.0±10.1 | 0.0±0.0 | 11.9±8.8 | ||
| 2n↔2n chimeras | ||||||||||
| TrB-8 | 29.4 | 28.6 | 38.1 | 0.0 | 45.5 | 98.2 | 22.5 | 83.8 | ||
| TrC-5 | 31.0 | 7.5 | 31.9 | 20.6 | 28.7 | 40.0 | 0.0 | 14.4 | ||
| TrC-34 | 38.2 | 42.7 | 33.3 | 85.1 | 78.2 | 16.4 | ND | 30.9 | ||
| TrC-21 | 43.5 | 45.9 | 41.3 | 59.8 | 60.5 | 68.4 | 39.9 | 73.4 | ||
| TrB-9 | 92.0 | 93.4 | 77.1 | 12.8 | 22.2 | 18.0 | 0.0 | 0.0 | ||
| Mean±s.e.m. | 46.8±11.6 | 43.6±14.2 | 44.3±8.4 | 35.7±15.9 | 47.0±10.3 | 48.2±15.7 | 15.6±9.7 | 40.5±16.4 | ||
YS mes, yolk sac mesoderm; YS end, yolk sac endoderm; P end, parietal endoderm; PT, placental trophoblast; PTGC, placental trophoblast giant cells; RMGC, trophoblast giant cells overlying Reichert's membrane; ND, not done.
a
Triploid↔2n chimera TrC-25 is not included in the table. It was damaged and so not analysed.
b
Abnormal placental development; an allantoic vesicle was present, which had not fused normally with the chorion. These two tissues were scored separately, but uncorrected values are shown as there were no corresponding tissues in age-matched positive controls.